High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08
作者: Martin FehrHanne HawleStefanie HayozPeter Thuss-PatienceSabina SchacherJorge Riera KnorrenschildDonat DürrWolfram T. KnoefelHolger RumpoldMichael BitzerMartin ZweifelPanagiotis SamarasUlrich MeyMarc KüngRalph WinterhalderWolfgang EistererViviane HessMarie-Aline GérardArnoud TempletonMichael StahlThomas Ruhstaller
作者单位: 1Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland
2SAKK Coordinating Center, Bern, Switzerland
3Charité – Universitätsmedizin Berlin, Berlin, Germany
4Kantonsspital Winterthur, Winterthur, Switzerland
5Universitätsklinikum Giessen und Marburg, Marburg, Germany
6Stadtspital Triemli, Zürich, Switzerland
7Universitätsklinikum Düsseldorf, Düsseldorf, Germany
8Krankenhaus der barmherzigen Schwestern, Linz, Austria
9Landeskrankenhaus Feldkirch, Feldkirch, Austria
10Universitätsklinikum Tübingen, Tübingen, Germany
11Inselspital Bern, Bern, Switzerland
12Universitätsspital Zürich, Zürich, Switzerland
13Kantonsspital Graubünden, Chur, Switzerland
14Hôpital Fribourgeois, Villars-sur-Glâne, Switzerland
15Luzerner Kantonsspital, Luzern, Switzerland
16Medizinische Universität Innsbruck, Innsbruck, Austria
17Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
18Universitätsspital Basel, Basel, Switzerland
19Claraspital Basel, Basel, Switzerland
刊名: BMC Cancer, 2020, Vol.20 (Suppl 6), pp.3786-3793
来源数据库: Springer Nature Journal
DOI: 10.1186/s12885-020-6623-z
关键词: Oesophageal cancerAdenocarcinomaThrombosisVenous thrombosisThromboembolic eventsPreoperative therapyNeoadjuvant therapyCisplatinChemoradiotherapy
原始语种摘要: Abstract(#br)Background(#br)High rates of venous thromboembolic events (VTEs), mainly in advanced disease, are reported for patients with cancer of the upper gastrointestinal tract (stomach, pancreas) and for treatment with cisplatin. Methods(#br)Exploratory analysis of VTEs reported as adverse events and serious adverse events in a prospective, randomised, multicentre, multimodal phase III trial according to VTEs reported as adverse events and severe adverse events. Patients with resectable oesophageal cancer (T2N1–3, T3-4aNx) were randomized to 2 cycles of chemotherapy with docetaxel 75 mg/m2, cisplatin 75 mg/m2 followed by chemo-radiotherapy (CRT) and subsequent surgery (control arm) or the same treatment with addition of cetuximab (investigational arm)....
全文获取路径: Springer Nature  (合作)
影响因子:3.333 (2012)